PE20210550A1 - Compuestos de 4-metildihidropirimidinona y su uso farmaceutico - Google Patents

Compuestos de 4-metildihidropirimidinona y su uso farmaceutico

Info

Publication number
PE20210550A1
PE20210550A1 PE2020001289A PE2020001289A PE20210550A1 PE 20210550 A1 PE20210550 A1 PE 20210550A1 PE 2020001289 A PE2020001289 A PE 2020001289A PE 2020001289 A PE2020001289 A PE 2020001289A PE 20210550 A1 PE20210550 A1 PE 20210550A1
Authority
PE
Peru
Prior art keywords
methyldihydropyrimidinone
compounds
pharmaceutical use
pharmaceutically acceptable
pharmaceutical
Prior art date
Application number
PE2020001289A
Other languages
English (en)
Inventor
Takayuki Sakai
Taku Ikenogami
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20210550A1 publication Critical patent/PE20210550A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a compuestos de 4-metildihidropirimidinona o sus sales farmaceuticamente aceptables que tienen actividad antagonista de RORgamma, composiciones farmaceuticas que los comprenden y su uso farmaceutico. Se proporcionan un compuesto de la formula (1) o (2) o una de sus sales farmaceuticamente aceptables y una composicion farmaceutica que lo comprende.
PE2020001289A 2018-02-28 2019-02-27 Compuestos de 4-metildihidropirimidinona y su uso farmaceutico PE20210550A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035597 2018-02-28
PCT/JP2019/007433 WO2019167981A1 (ja) 2018-02-28 2019-02-27 ４－メチルジヒドロピリミジノン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
PE20210550A1 true PE20210550A1 (es) 2021-03-17

Family

ID=67805061

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001289A PE20210550A1 (es) 2018-02-28 2019-02-27 Compuestos de 4-metildihidropirimidinona y su uso farmaceutico

Country Status (18)

Country Link
US (2) US10899717B2 (es)
EP (1) EP3760616A4 (es)
JP (1) JP7282546B2 (es)
KR (1) KR20200126973A (es)
AR (1) AR114270A1 (es)
AU (1) AU2019228915A1 (es)
BR (1) BR112020016785A2 (es)
CA (1) CA3087994A1 (es)
CL (1) CL2020002187A1 (es)
CO (1) CO2020011860A2 (es)
IL (1) IL276323A (es)
MX (1) MX2020008982A (es)
PE (1) PE20210550A1 (es)
PH (1) PH12020551341A1 (es)
RU (1) RU2020131402A (es)
SG (1) SG11202007117RA (es)
TW (1) TW202000650A (es)
WO (1) WO2019167981A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
WO2021149786A1 (en) 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485107A (en) 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
TWI423819B (zh) 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
US20100010024A1 (en) 2006-07-01 2010-01-14 Bayer Healthcare Ag Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension
DE102006031314A1 (de) 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie
WO2009150668A1 (en) 2008-06-13 2009-12-17 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
EP2719690A4 (en) 2011-04-28 2014-12-31 Japan Tobacco Inc AMIDE COMPOUND AND USE THEREOF IN PHARMACY
EP2682389A1 (en) 2012-07-02 2014-01-08 Commissariat A L'energie Atomique Et Aux Energies Alternatives Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
WO2014065413A1 (ja) 2012-10-26 2014-05-01 日本たばこ産業株式会社 トリアゾール・イソオキサゾール化合物およびその医薬用途
CN103113308B (zh) 2013-01-25 2014-11-19 浙江大学 一种制备二氢嘧啶酮衍生物的方法
US20160168089A1 (en) 2014-12-12 2016-06-16 H. Lundbeck A/S Process for the manufacture of idalopirdine
KR102551018B1 (ko) 2014-12-12 2023-07-05 니뽄 다바코 산교 가부시키가이샤 디히드로피리미딘-2-온 화합물 및 그의 의약 용도
MX2017007623A (es) 2014-12-12 2018-09-26 Regenacy Pharmaceuticals Llc Derivados de piperidina como inhibidores de hdac1/2.
US10532052B2 (en) 2014-12-12 2020-01-14 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor

Also Published As

Publication number Publication date
EP3760616A1 (en) 2021-01-06
SG11202007117RA (en) 2020-08-28
WO2019167981A1 (ja) 2019-09-06
TW202000650A (zh) 2020-01-01
JP7282546B2 (ja) 2023-05-29
CO2020011860A2 (es) 2021-01-18
CA3087994A1 (en) 2019-09-06
AR114270A1 (es) 2020-08-12
US20210363110A1 (en) 2021-11-25
US10899717B2 (en) 2021-01-26
IL276323A (en) 2020-09-30
MX2020008982A (es) 2020-09-28
EP3760616A4 (en) 2021-11-03
RU2020131402A (ru) 2022-03-24
US20190300488A1 (en) 2019-10-03
CL2020002187A1 (es) 2020-12-18
PH12020551341A1 (en) 2021-06-21
CN111741947A (zh) 2020-10-02
AU2019228915A1 (en) 2020-07-02
BR112020016785A2 (pt) 2021-02-09
JP2019151623A (ja) 2019-09-12
KR20200126973A (ko) 2020-11-09

Similar Documents

Publication Publication Date Title
CO2022003782A2 (es) Inhibidores de kras g12d
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
DOP2022000115A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CO2020011860A2 (es) Compuestos de 4–metildihidropirimidinona y su uso farmacéutico
DOP2019000184A (es) Inhibidores selectivos de jak1
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
UY35275A (es) Derivados de aminopirazina
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
CL2020002188A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico.
BR112020008258B8 (pt) Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
CY1126071T1 (el) Φαρμακευτικα σκευασματα αναλογων κυκλοσπορινης
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.